According to the American Cancer Society, an estimated 5,480 new cancer cases will be diagnosed daily in the United States alone in 2024.
With the global cancer burden escalating, the need for effective supportive care in oncology is more pressing than ever. One of the most common and painful side-effects of cancer treatment is mouth sores, medically known as oral mucositis, affecting a significant percentage of patients undergoing chemotherapy and radiotherapy. Recent studies have highlighted the potential of BLIS K12™ in providing much-needed relief for this condition.
Oral mucositis, characterized by redness, swelling, and ulcerations of the oral mucosa, is a common side effect of cancer treatments. It can severely impact a patient’s quality of life, often leading to difficulties in swallowing and requiring alternative nutritional support. Currently, about 40% of chemotherapy patients and 30-60% of radiotherapy patients develop this condition, with limited effective treatments available.
